Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders

Partnership will combine n-Lorem's cutting-edge antisense oligonucleotide (ASO) technology and Servier's R&D expertise with the aim of advancing ASO technology and delivering precision medicine approaches for patients across the world. Servier strengthens its commitment to rare...